Prohibition against competing cancer clinical trials

Competing commitments in clinical trials.

Parametric Competing Risks Models in Clinical Trials

Some fully general parametric competing risks models, which allow the underlying (possibly dependent) lifetimes to be modeled as a function of an arbitrary number of covariables, are formulated, and their resulting likelihood function is derived. Under carefully stated regularity conditions, large sample tests of hypotheses concerning the model parameters are obtained for the single point trunc...

Evaluation of Clinical Trials

In a number of important clinical issues such as evaluation of the efficacy or effectiveness of therapeutic or preventive interventions as well as for comparing the harms of interventions, randomized controlled trials (RCTs) provide the highest levels of evidence, either directly or indirectly. It is obvious that critical appraisal of these studies to assess their validity and precision is of p...

Competing risk and heterogeneity of treatment effect in clinical trials

It has been demonstrated that patients enrolled in clinical trials frequently have a large degree of variation in their baseline risk for the outcome of interest. Thus, some have suggested that clinical trial results should routinely be stratified by outcome risk using risk models, since the summary results may otherwise be misleading. However, variation in competing risk is another dimension o...

Clinical trials in cancer.

Randomized controlled trials (RCTs) in cancer are expensive, slow, and often preclude other exploratory investigations that might be valuable. Two types of RCTs should not be conducted. When the results of exploratory studies are so dramatically different from all prior experience, RCTs should be done to improve upon the new finding but not to allocate some patients to inferior control arms to ...